Stem Cell Therapy, BMAC & Adipose Tissue Scaffolding
“Stem cell therapy” is the term many patients search for when seeking advanced regenerative care, but it can make the treatment sound more standardized than it really is. At Wellward, these treatments use cells, growth signals, and supportive tissue collected from your own bone marrow or fat during the same visit. The preparation is then placed into carefully selected joints, tendons, ligaments, or spinal structures when the tissue may still have a reasonable opportunity to heal.
BMAC: Bone Marrow Aspirate Concentrate
ATS: Adipose Tissue Scaffolding
Same-Day From Your Own Body
When It May Be Considered
- Selected moderate or more complex joint degeneration
- Disc, ligament, tendon, or other tissue injury where a more concentrated preparation made from your own tissue is reasonable
- Prior conservative care or simpler biologic treatment has not been enough
- The diagnosis, tissue quality, and recovery plan support a regenerative approach
What It Cannot Promise
No biologic injection can guarantee cartilage regrowth, reverse every stage of arthritis, or replace surgery when the structure is no longer salvageable. The biologic preparation is one part of the plan. Target selection, protection, progressive loading, movement quality, sleep, metabolic health, and follow-through influence whether the treatment can translate into durable function.
When It May Not Be the Right Fit
How This Fits Into a Broader Plan
Risks and Limitations
Frequently Asked Questions
BMAC is a concentrated bone-marrow preparation. ATS uses your own adipose tissue as a biologically active scaffold. The target tissue and treatment goal help determine which is more appropriate.
It is usually self-pay. Costs and alternatives are reviewed before scheduling
Start by finding out which tissue is actually limiting recovery—and whether BMAC or ATS is a reasonable fit.
These procedures use self-derived tissue obtained and used during the same clinical encounter. We explain exactly what is being collected and how it is prepared rather than presenting it as an FDA-approved drug product.
It depends on how advanced the damage is. Earlier-stage problems may offer a better opportunity for improvement, while severe bone-on-bone arthritis is less predictable and may be better treated another way. Your evaluation helps determine whether the potential benefit is realistic.